Monotherapy Etoricoxib

Phase 3Small molecule

LLaboratorios Silanes S.A. de C.V.

Monotherapy Etoricoxib is one of 8 small molecule programs targeting Tendinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TendinitisActive, not recruiting

TendinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Tendinitis

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

—2

Nitrostat

VViatris Specialty LLC

Approved

—3

Oruvail

WWyeth-Lederle Vaccines

Approved

—4

Methylprednisolone Acetate

MMontefiore Medical Center

Approved

1 5

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 3

1 6

Monotherapy Etoricoxib

LLaboratorios Silanes S.A. de C.V.

Phase 3

1 7

Platelet Rich Plasma

ZZagazig University

Preclinical

1 8

Depo Medrol

BBrii Biosciences Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tendinitis1 trial

Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

Completed·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT07328022·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Monotherapy Etoricoxib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Monotherapy Etoricoxib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Monotherapy Etoricoxib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratorios Silanes S.A. de C.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaboratorios Silanes S.A. de C.V.

Monotherapy Etoricoxib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tendinitis1 trial

References

Drug Info

Quick Facts

Related News